Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19625795 | 0.86 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3OPRM1DRD4 | |
| SCHEMBL11246658 | 0.83 | SLC6A4 (0.68) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL11246645 | 0.83 | SLC6A4 (0.68) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL11463570 | 0.82 | SLC6A4 (0.66) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL11535102 | 0.82 | SLC6A4 (0.75) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL11185245 | 0.82 | SLC6A4 (0.75) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL11185241 | 0.82 | SLC6A4 (0.75) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| SCHEMBL11185531 | 0.82 | SLC6A4 (0.75) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| Bromide SCHEMBL11252035 | 0.82 | SLC6A4 (0.66) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 | |
| Bromide SCHEMBL11266393 | 0.82 | SLC6A4 (0.66) | SLC6A2SLC6A4SLC6A3OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691893-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-7691893-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-7691893-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | BERTANI BARBARA | 2010-02-11 | — | — | US | disclosed |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | BERTANI BARBARA | 2010-02-11 | — | — | US | disclosed |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | BERTANI BARBARA | 2010-02-11 | — | — | US | disclosed |
| EP-2064186-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | Glaxo Group Limited (GB) | 2009-06-03 | — | — | EP | disclosed |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| WO-2008031772-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008031772-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114049-A1 | CHEMICAL COMPOUNDS | SLC6A2, HTR3C, SLC6A3 | SLC6A2 1/4885SLC6A4 11/4885SLC6A3 3/4885 |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | SLC6A2, NPY5R, SLC6A3 | SLC6A2 1/4885SLC6A4 14/4885SLC6A3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.